UPDATE: THE COVID-19 DETECTION FOUNDATION (dba VIRUFY) and BARDA ANNOUNCE CONTRACT to RESEARCH & DEVELOP COVID-19 SCREENING THROUGH AI/MACHINE LEARNING

The COVID-19 Detection Foundation (dba Virufy), a 501(c)(3) non-profit research organization (https://virufy.org) developing a smartphone app for rapid COVID-19 screening through artificial intelligence (AI) / machine learning (ML) technology, today announced that it has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary … Read more

Global Advanced Metals and Croom Medical Collaborate to Offer Tantalum Additive Manufacturing Capability

Global Advanced Metals (USA) and Croom Medical (Ireland) are collaborating to establish a turnkey tantalum-based additive manufacturing (AM) platform. A laser powder bed fusion GE M2 Series 5 printer has been installed within Croom’s facility, with the printer being fully dedicated to the use of GAM’s tantalum AM powder. With Croom’s years of successful contract … Read more

1nHealth Partners With The Mighty to Bring Fresh Patient Centricity to Clinical Trial Recruitment

Clinical trials bring hope to patients by exposing them to potentially groundbreaking therapies. Thus, it can be especially devastating for patients to learn about a clinical trial and then fail to qualify for participation.   1nHealth and The Mighty have teamed up to route patients who may not qualify for a specific trial to condition-focused communities … Read more

Amber Ophthalmics Announces Positive Topline Phase 2 Data Evaluating NEXAGON® for the Treatment of Persistent Corneal Epithelial Defect (PCED)

Amber Ophthalmics, Inc. (Amber), a privately held clinical-stage biopharmaceutical company focused on developing innovative therapies for rare ophthalmic diseases, today announced positive topline results from the Phase 2 randomized, double-masked, vehicle-controlled clinical trial (EXPEDE) evaluating two topically administered concentrations of NEXAGON® (lufepirsen ophthalmic gel) for the treatment of persistent corneal epithelial defect (PCED), secondary to … Read more

Ketamine Media Scheduled to Launch North America’s Largest Psilocybin Awareness Network

Ketamine Media announced today that it is in the final stages of launching its digital ecosystem of premium online properties to raise awareness about the clinical use of psilocybin at scale.  Ketamine Media entered the psychedelic medicine space in 2016 to help providers raise awareness about the clinical use of ketamine. With nearly 200 clinics … Read more

CfPIE Introduces New Course on Ethics in Medical Research

The Center for Professional Innovation and Education (CfPIE), a global leader in life sciences training, has announced a new two-day virtual course addressing responsible, ethical conduct in research. Ethics in Research — Values for Responsible Conduct of Research will provide participants with the necessary concepts and vocabulary to engage with ethical challenges along with the … Read more

Study Investigates New Approach to Diagnosis and Treatment of Head and Neck Cancers

A recently published article in Experimental Biology and Medicine (Volume 246, Issue 24, December, 2021) investigates a new approach for treating nasopharyngeal carcinoma. The study, led by Dr. Yan-Ping Mao, from the Sun Yat-sen University Cancer Center in Guangzhou (China), reports that BART10-3p, an Epstein-Barr virus-encoded microRNA, is an unfavorable prognostic indicator for nasopharyngeal cancer … Read more

Protecting the brain in sickle cell anemia: the value of beginning early in life

A recently published article in Experimental Biology and Medicine (Volume 246, Issue 23, December, 2021) highlights the importance of early-in-life screening for brain damage in children with sickle cell.  The study, led by Dr. Jane Hankins in the Department of Hematology at St. Jude Children’s Research Hospital (SJCRH) in Memphis, along with colleagues at SJCRH, … Read more

Rome Foundation Releases Clinical Criteria to Better Meet Needs of Patients

The Rome Foundation has published a groundbreaking modification of the Rome IV diagnostic criteria of the Disorders of Gut Brain Interaction (DGBI – formerly Functional GI disorders) designed specifically for clinical practice. These new criteria use the same symptoms as the standard Rome IV diagnostic criteria but suspend the required duration and frequency of requirements. Currently, … Read more

Direct Biologics, LLC Announces One Year Follow Up of Pilot Safety Study of ExoFlo for Treatment of Osteoarthritis in Combat-Related Injuries

Direct Biologics, LLC, a market-leading biotech company in the field of regenerative biologics, announced the publication of the one-year follow-up results from a pilot safety study of a MSC-derived EVIP for treatment of OA in combat-related injuries in the Journal of Stem Cell Research. This publication follows the first report on the safety and clinical … Read more